Clarithromycin in treatment of early Lyme disease: a pilot study.
Forty-one patients with erythema migrans were enrolled in an open-labelled pilot study of oral clarithromycin, 500 mg twice daily for 21 days, for the treatment of early Lyme disease. Immediately posttherapy, pretreatment signs and symptoms resolved among 91% of the 33 evaluable patients. At 6 months, all 28 of the evaluable patients were well. Clarithromycin shows promise as an effective agent for the treatment of early Lyme disease and warrants further study.
Dattwyler
R J
RJ
Lyme Disease Center, State University of New York at Stony Brook 11794-8161, USA.
Grunwaldt
E
E
Luft
B J
BJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008193:Lyme Disease / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D017291:Clarithromycin